Research programme: cardiovascular disease gene therapy - Boehringer Ingelheim/Inovio

Drug Profile

Research programme: cardiovascular disease gene therapy - Boehringer Ingelheim/Inovio

Alternative Names: Cardiovascular disease gene therapy - Boehringer Ingelheim/Inovio

Latest Information Update: 18 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim; Inovio Biomedical Corporation
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 18 Aug 2009 Discontinued - Preclinical for Cardiovascular disorders (unspecified route)
  • 18 Aug 2009 Discontinued - Preclinical for Cardiovascular disorders in Germany (unspecified route)
  • 04 Apr 2005 Genetronics Biomedical Corporation is now called Inovio Biomedical Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top